Abstract
The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.
| Original language | English |
|---|---|
| Pages (from-to) | 703-709 |
| Number of pages | 7 |
| Journal | Mini-Reviews in Medicinal Chemistry |
| Volume | 4 |
| Issue number | 7 |
| Publication status | Published - Sep 2004 |
Fingerprint
Keywords
- Acute coronary syndromes
- Atherosclerotic plaque
- Glycoprotein IIb/IIIa receptor
- Percutaneous coronary intervention
- Platelet aggregation inhibitors
ASJC Scopus subject areas
- Chemistry(all)
- Medicine (miscellaneous)
- Pharmacology
Cite this
Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor : Rationale for their use in clinical cardiology. / Rossi, Marco L.; Zavalloni, D.
In: Mini-Reviews in Medicinal Chemistry, Vol. 4, No. 7, 09.2004, p. 703-709.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor
T2 - Rationale for their use in clinical cardiology
AU - Rossi, Marco L.
AU - Zavalloni, D.
PY - 2004/9
Y1 - 2004/9
N2 - The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.
AB - The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.
KW - Acute coronary syndromes
KW - Atherosclerotic plaque
KW - Glycoprotein IIb/IIIa receptor
KW - Percutaneous coronary intervention
KW - Platelet aggregation inhibitors
UR - http://www.scopus.com/inward/record.url?scp=4344629332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4344629332&partnerID=8YFLogxK
M3 - Article
C2 - 15379638
AN - SCOPUS:4344629332
VL - 4
SP - 703
EP - 709
JO - Mini-Reviews in Medicinal Chemistry
JF - Mini-Reviews in Medicinal Chemistry
SN - 1389-5575
IS - 7
ER -